Recombinant Human IFN-a2b

Catalog No: #70604

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	Recombinant Human IFN-a2b
Brief Description	Recombinant Protein
Host Species	E.coli
Purification	> 96 % by SDS-PAGE and HPLC analyses.
Target Name	rHu IFN-a2b
Other Names	Vascular Endothelial Growth Factor is a sub-family of growth factors produced by cells, which stimulates vasculogenesis and angiogenesis. VEGF's normal function is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (co
Accession No.	accession:P01563 GeneID:3440
Uniprot	P01563
GeneID	3440;
Calculated MW	Approximately 19.4 kDa, a sing
SDS-PAGE MW	Sterile Filtered White lyophil
Target Sequence	MCDLPQTHSL GSRRTLMLLA QMRRISLFSC LKDRHDFGFP QEEFGNQFQK AETIPVLHEM IQQIFNLFST KDSSAAWDET LLDKFYTELY QQLNDLEACV IQGVGVTETP LMKEDSILAV RKYFQRITLY LKEKKYSPCA WEVVRAEIMR SFSLSTNLQE SLRSKE
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4.
Storage	This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze thaw cycles.

Background

IFN-αs are proteins secreted by leukocyte. They are mainly involved in innate immune response against viral infection. The IFN-α family has 13 subtypes and 23 different variants. The individual proteins have molecular masses between 19-26 kDa and consist of proteins with lengths of 156-166 and 172 amino acids. All IFN-α subtypes possess a common conserved sequence region between amino acid positions 115-151 while the amino-terminal ends are variable. Many IFN-alpha subtypes differ in their sequences at only one or two positions. Naturally occurring variants also include proteins truncated by 10 amino acids at the carboxy-terminal end.

References

1. Tarhini AA, Gogas H, Kirkwood JM. 2012. J Immunol, 189: 3789-93.
2. Tohyama M, Yang L, Hanakawa Y, et al. 2012. J Invest Dermatol, 132: 1933-5.
3. Corssmit EP, Heijligenberg R, Hack CE, et al. 1997. Clin Exp Immunol, 107: 359-63.
4. Corssmit EP, de Metz J, Sauerwein HP, et al. 2000. J Interferon Cytokine Res, 20: 1039-47.